Edition:
United States

Hologic Inc (HOLX.OQ)

HOLX.OQ on NASDAQ Stock Exchange Global Select Market

45.01USD
21 Jul 2017
Change (% chg)

$-0.40 (-0.88%)
Prev Close
$45.41
Open
$45.35
Day's High
$45.58
Day's Low
$44.96
Volume
616,459
Avg. Vol
710,967
52-wk High
$46.80
52-wk Low
$35.15

Latest Key Developments (Source: Significant Developments)

Hologic says holders of 2 % convertible exchange senior notes due 2042 are eligible to convert
Monday, 3 Jul 2017 01:00pm EDT 

July 3 (Reuters) - Hologic Inc :Hologic delivers notice that holders of 2.00% convertible exchange senior notes due 2042 are eligible to convert.Hologic inc - conversion right triggered because closing price of co's stock exceeded about $40.53, which is 130% of conversion price for notes.Hologic-Current conversion rate for notes is 32.07698 shares of common stock per $1,000 principal amount outstanding, which is equivalent to about $31.18/share.  Full Article

Hologic obtains CE mark in Europe for Panther Fusion System
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - Hologic Inc ::Obtained a CE mark in Europe for its new Panther Fusion System and Panther Fusion Assays for flu and respiratory testing.  Full Article

Hologic receives expanded FDA clearance to market Cynosure's Sculpsure
Thursday, 15 Jun 2017 08:00am EDT 

June 15 (Reuters) - Hologic Inc -:Hologic receives expanded FDA 510(k) clearance to market Cynosure's Sculpsure® for non-invasive body contouring (lipolysis) of back, inner and outer thighs.  Full Article

Hologic Inc updates on FDA's approval of Genius 3D mammography exam
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Hologic Inc ::FDA approves Hologic's Genius™ 3D mammography™ exam as the only mammogram superior for women with dense breasts*.  Full Article

Hologic announces Q2 revenue $715.4 million
Wednesday, 10 May 2017 04:03pm EDT 

May 10 (Reuters) - Hologic Inc :Hologic announces financial results for second quarter of fiscal 2017.Q2 GAAP earnings per share $1.84.Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S.Q2 revenue $715.4 million versus I/B/E/S view $685.4 million.Q2 non-GAAP earnings per share $0.50.Sees 2017 GAAP revenue $3,050 to $3,080 million.Sees 2017 GAAP EPS $2.44 to $2.48.Sees 2017 non-GAAP EPS $1.98 to $2.02.Sees 2017 non-GAAP revenue $3,050 to $3,080 million.Sees Q3 non-GAAP revenue $790 to $805 million.Sees Q3 non-GAAP EPS $0.48 to $0.50.Sees Q3 GAAP EPS $0.22 to $0.24.Sees Q3 GAAP revenue $790 to $805 million.FY2017 earnings per share view $1.97, revenue view $3.06 billion -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.50, revenue view $815.5 million -- Thomson Reuters I/B/E/S.  Full Article

Cynosure says Compensation Committee established $13 mln cash pool from making severance payments related to Hologic deal
Wednesday, 22 Feb 2017 05:04am EST 

Cynosure Inc : Cynosure - Compensation committee established $13 million cash pool from making severance payments for persons without employment agreements relating to Hologic deal Source: (http://bit.ly/2lL68PF) Further company coverage: [CYNO.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cynosure agrees to termination fee of $57.7 mln for Hologic deal
Tuesday, 14 Feb 2017 05:00pm EST 

Cynosure Inc :Hologic - upon termination of deal under specified circumstances Cynosure has agreed to pay co termination fee of about $57.7 million.  Full Article

Hologic to acquire Cynosure for $1.65 bln
Tuesday, 14 Feb 2017 07:50am EST 

Hologic Inc : Hologic to acquire Cynosure, leader in medical aesthetics systems and technologies, in all-cash tender offer that combines two complementary businesses . Deal for enterprise value of $1.44 billion net of cash . Deal for $66.00 per share . Deal immediately accretive to non-GAAP earnings per share . Transaction has been approved unanimously by boards of directors of both companies . Hologic expects to realize annualized cost synergies of approximately $25 million by third year after close . Deal corresponds to an equity value of approximately $1.65 billion . Says Cynosure will merge with a subsidiary of Hologic and become a wholly-owned subsidiary of Hologic . Transaction is expected to be fully funded with cash on hand, including proceeds from recently completed blood screening divestiture . Says following completion of transaction, Cynosure shares will be delisted from Nasdaq . Hologic forecasts deal adding approximately $0.03 to $0.05 to company's non-GAAP EPS in balance of fiscal 2017 . Under terms of agreement, unit to start tender offer to purchase outstanding shares of Cynosure common stock for $66/share in cash . Estimates that deal will enable company to accelerate pro-forma revenue growth by roughly 150 basis points over next several years . Estimates that deal will enable company to increase non-GAAP earnings per share (EPS) at "solid" double-digit rate over next several years.  Full Article

Hologic reports Q1 GAAP EPS of $0.30
Wednesday, 1 Feb 2017 04:01pm EST 

Hologic Inc : Sees FY 2017 revenue $2.79 billion to $2.83 billion . Qtrly revenue of $734.4 million increased 5.6%, or 6.3% in constant currency terms . Hologic announces financial results for first quarter of fiscal 2017 . Q1 non-GAAP earnings per share $0.52 . Q1 GAAP earnings per share $0.30 . Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Q1 revenue $734.4 million versus I/B/E/S view $724.2 million . Constant currency guidance assumes that foreign exchange rates are same in fiscal 2017 as in fiscal 2016 . Sees FY 2017 earnings per share $2.73 to $2.77 . FY2017 earnings per share view $2.15, revenue view $2.96 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $1.90 to $1.94 . "We forecast that divestiture of Blood Screening Business will accelerate both our top- and bottom-line growth rates" . Sees Q2 revenue $675 million to $685 million .Sees Q2 earnings per share $1.85 to $1.86.  Full Article

Hologic Q1 non-gaap EPS $0.52
Wednesday, 1 Feb 2017 04:01pm EST 

Hologic Inc : Hologic announces financial results for first quarter of fiscal 2017 . Qtrly revenue of $734.4 million increased 5.6 pct, or 6.3 pct in constant currency terms . Q1 non-gaap earnings per share $0.52 . Q1 gaap earnings per share $0.30 . Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Q1 revenue $734.4 million versus I/B/E/S view $724.2 million . Constant currency guidance assumes that foreign exchange rates are same in fiscal 2017 as in fiscal 2016 . Sees FY 2017 revenue $2.79 billion to $2.82 billion . Sees FY 2017 earnings per share $2.73 to $2.77 . FY2017 earnings per share view $2.15, revenue view $2.96 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $1.90 to $1.94 . Hologic Inc- "we forecast that divestiture of blood screening business will accelerate both our top- and bottom-line growth rates" . Sees Q2 revenue $675 million to $685 million .Sees Q2 earnings per share $1.85 to $1.86.  Full Article

BRIEF-Hologic obtains CE mark in Europe for Panther Fusion System

* Obtained a CE mark in Europe for its new Panther Fusion System and Panther Fusion Assays for flu and respiratory testing Source text for Eikon: Further company coverage: